Home Featured Page 39

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

What You Need to Know About Massachusetts’ Question 4 and the...

Psychedelics Take Centre Stage in Massachusetts’ Local Media

Psychedelic Education Through a Healing Justice Lens

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug...

How Shadow Work Can Be a Powerful Tool for Psychedelic Transformation

The FDA, MDMA, and Public Perception: Was the FDA Fair to...

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote...

Protecting Indigenous Wisdom: Rethinking Psychedelic Legalization

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms:...

The Science Behind How Psychedelics Inspire Creative Breakthroughs

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

What You Need to Know About Massachusetts’ Question 4 and the...

Psychedelics Take Centre Stage in Massachusetts’ Local Media

Psychedelic Education Through a Healing Justice Lens

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug...

How Shadow Work Can Be a Powerful Tool for Psychedelic Transformation

The FDA, MDMA, and Public Perception: Was the FDA Fair to...

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote...

Protecting Indigenous Wisdom: Rethinking Psychedelic Legalization

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms:...

The Science Behind How Psychedelics Inspire Creative Breakthroughs

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY